AltruBio

AltruBio to Present at Biotech Showcase™ 2023

AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases

AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis

Life Science Leader─Industry outlook 2023

Linkedin─Developing Novel Treatments for Immunological Disorders

AltruBio to Present at Stifel 2022 Healthcare Conference

AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168) in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

AltruBio President and CEO Judy Chou Appointed to the Governing Board of California’s Stem Cell & Gene Therapy Agency

Pharma’s almanac─What key indicators do you look at to predict the future of this industry

CIRM─Judy Chou, Ph.D., Appointed to Governing Board of California’s Stem Cell & Gene Therapy Agency

AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

BioSpace─AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

Labiotech.eu─ Top 10 biotech companies in Taiwan

Podcast─Identifying Targets on Problematic T Cells to Treat Immunological Diseases with Dr. Judy Chou AltruBio

Bioprocess Online─Overcoming Platform Inefficiencies In mAb Manufacturing

AltruBio to Present at the 2022 BIO International Convention

AltruBio Announces Completion of Enrollment in Phase 1 Clinical Study of Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

BioProcess International─Manufacturing must align with new modalities to drive efficiency, AltruBio

AltruBio to Present at BioProcess International US West 2022

BioSpace─Three Influential Women of Biopharma Breaking Down the Executive Barrier

Scrip Asks ─ What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

AltruBio to Present at BIO CEO & Investor Conference

BioSpace ─ BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

AltruBio to Present at Biotech Showcase™ 2022

BioSpace ─ Top Life Sciences Startups to Watch in 2022

Life Science Leader─What Trends Are 9 Biopharma CEOs Paying Attention To?

Podcast─CMC Developability Assessments For Rapid Ph.1 Entry With AltruBio's Gene Lee, Ph.D.

AltruBio to Present Abstract on Checkpoint Regulator Neihulizumab as a Novel Therapy for Immunological Diseases at the B&T Cell-Mediated Autoimmune Disease Drug Development Virtual Summit

BioPharm International─Trends in Outsourcing of Bioprocess Development

Bioprocess Online─mAb 2.0 For Psoriatic Arthritis

Podcast─From Bayer To Startup Bio With AltruBio's Dr. Judy Chou

AltruBio Continues to Strengthen Management Team With the Appointment of Jesse Hall, M.D., as Chief Medical Officer

Fierce Biotech─AltruBio snags a CMO after pivot from oncology to immunology

Life Science Leader─Companies To Watch: AltruBio

AltruBio Strengthens Management Team With Appointment of Jeroen Grasman as Chief Financial Officer

ALTRUBIO RAISES $63 MILLION SERIES A ROUND TO CONTINUE ITS COMPANY TRANSFORMATION

Endpoints News─After a major facelift, AltruBio says it's ready for a pivotal fight against graft-versus-host disease

Fierce Biotech─New name, new board, new focus: AltruBio relaunches with $63M series A

AltruBio’s Neihulizumab Granted Fast Track Designation by the FDA for Steroid Refractory Acute Graft Versus Host Disease

AltruBio to present at Biotech Showcase Digital 2021.

AltruBio Presented its Novel PSGL-1 Agonist Antibody Program for Immunological Diseases at FOCIS and Presented its Phase 2a Psoriatic Arthritis study results for lead molecule, Neihulizumab (AbGn-168H), at ACR.

AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.

AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a results

AltruBio Inc. presented AbGn-107 Phase 1a chemo-refractory GI cancer results at ASCO-GI 2020

AltruBio’s presentation on Neihulizumab Phase 2a Ulcerative colitis results selected as Poster of Distinction at Digestive Disease Week (DDW) 2020

AbGenomics Holding Inc. Announces Company Name Change to AltruBio Inc.

The Business Journals─Bayer site head in Berkeley jumps to Peninsula cancer drug developer

Abgenomics welcomes Dr. Judy Chou as new President/CEO

AbGenomics Presented Latest Research Findings on the preliminary Phase I Clinical progress of AbGn-107 at the World ADC Asia 2018

AbGenomics Highlights AbGn-107 at the 2018 Protein Engineering Summit

AbGenomics CMO Dr. Shih-Yao Lin spoke at the 6th Annual Biologics World Taiwan

FDA Grants AbGenomics AbGn-168H (Neihulizumab) Orphan Drug Designation

AbGenomics Announces FDA Acceptance to Commence Phase I Clinical Trial of AbGn-107 ADC Candidate for Pancreatic, Gastric, and Colorectal Cancer Treatments

AbGenomics Announces Promising Final Results from their Phase II Open-Label Clinical Study of AbGn-168H / Neihulizumab in Psoriatic Arthritis, a T-cell Mediated Disease

AbGenomics Announces initiation of phase-Ib/IIa clinical trial of Neihulizumab (AbGn-168H) for the treatment of steroid refractory acute GvHD (aGvHD)

AbGenomics Announces IND Filing for AbGn-168H (Neihulizumab) to Treat Psoriatic Arthritis

AbGenomics Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans

AbGn-168 Phase I Trial Initiate